If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Cathal Friel of Open Orphan and Philip Haydn-Slater of Riverfort Global Opportunities
Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) talks about the signing of a contract with Carna Bioscience which is expected to deliver significant revenue for the Company.
Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services businesses. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
Philip Haydn-Slater, Non-Executive Chairman of Riverfort Global Opportunities (RGO) describes their progress in the third quarter of this year.
Riverfort Global Opportunities is Investment company listed on AIM and invests by providing equity-linked debt funding to public and private small cap growth companies in the technology, natural resources, energy, financial and healthcare industry sectors.
(Interview starts at 10 minutes 6 seconds)